RNS Number : 0909H
OptiBiotix Health PLC
29 July 2019

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Transfer of certain SkinBioTherapeutics plc shares

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that a portion of its shareholding in SkinBioTherapeutics plc consisting of 20,438,496 ordinary shares representing 15.88% of SkinBioTherapeutics plc's total issued share capital, have been dematerialised and transferred to a nominee CREST account (Pershing Nominees). OptiBiotix plc remains the beneficial owner of the transferred 20,438,496 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 49,794,190 representing 38.9% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive *Contact via Walbrook below*

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner / Ludovico Lazzaretti Tel: 020 7213 0880

finnCap (Broker)
Geoff Nash / Kate Bannatyne (Corporate Finance)
Tel: 020 7220 0500
Camille Gochez (Corporate Broking)

goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel

Walbrook PR Ltd
Anna Dunphy Mob: 07876 741 001

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCGMGZNKLMGLZM